Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Immunoglobulins, specifically Varicella-Zoster Immune Globulin (VZIG), are scientifically validated for use in preventing or modifying chickenpox (varicella) in certain high-risk populations. VZIG contains high titers of antibodies against the varicella-zoster virus and is recommended for individuals who have been exposed to chickenpox but are at increased risk for severe disease and cannot receive the varicella vaccine. These groups include immunocompromised individuals, pregnant women without immunity, and newborns whose mothers develop varicella around the time of delivery.

Clinical studies and post-exposure prophylaxis protocols have demonstrated that administration of VZIG within 10 days of exposure can reduce the severity of chickenpox or prevent the disease altogether in these vulnerable populations. The Centers for Disease Control and Prevention (CDC) and other health authorities endorse the use of VZIG based on this evidence, and its use is included in clinical guidelines.

For the general population, immunoglobulins are not routinely used to treat chickenpox, as most healthy children and adults recover without complications. The evidence for VZIG is strongest in post-exposure prophylaxis rather than treatment of established varicella infection, and it is not considered a substitute for vaccination. The rating of 4 reflects robust evidence in specific populations, but not for general use or for treating active, uncomplicated chickenpox.

More about Immunoglobulins
More about Chicken Pox

Other ingredients used for Chicken Pox

Other health conditions supported by Immunoglobulins

Products containing Immunoglobulins